Insulin aspart, recombinant Subcutaneous and Pramlintide Acetate

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using pramlintide together with insulin or certain other diabetes medications may increase the risk of hypoglycemia, or low blood sugar. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should monitor your blood glucose frequently (for example, before and after meals and at bedtime), particularly when you first start treatment with pramlintide and whenever the dose is increased. Let your doctor know if you experience frequent episodes of hypoglycemia. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: The hypoglycemic effect of insulin may be potentiated by amylin analogs such as pramlintide. Although pramlintide does not cause hypoglycemia on its own, it can increase the risk by slowing the rate of gastric emptying and suppressing postprandial glucagon secretion. The risk of developing severe hypoglycemia is the greatest in patients with type 1 diabetes and is usually seen within the first 2 to 3 hours following an injection of pramlintide.

MANAGEMENT: To reduce the risk of hypoglycemia, it is recommended that mealtime insulin doses be decreased by 50% when initiating pramlintide. Blood glucose should be monitored frequently, including pre- and post-meals and at bedtime, particularly upon initiation of pramlintide therapy and following a dose increase. After the initial 50% reduction in mealtime insulin dose, further adjustments of insulin dose should be individualized based on glycemic control and tolerability of the antidiabetic regimen. An increased frequency of mild-to-moderate hypoglycemia should be viewed as a warning sign of increased risk for severe hypoglycemia. Pramlintide should be discontinued if a patient experiences recurrent unexplained hypoglycemia that requires medical assistance. If pramlintide therapy is temporarily discontinued for any reason (e.g., surgery or illnesses), the same initiation protocol should be followed when therapy is reinstituted.

Insulin aspart, recombinant Subcutaneous

Generic Name: insulin aspart

Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch

Synonyms: Insulin aspart, Insulin Aspart

What is Insulin aspart, recombinant Subcutaneous?

Pramlintide Acetate

Generic Name: pramlintide

Brand name: SymlinPen 120, SymlinPen 60, Symlin

Synonyms: Pramlintide

What is Pramlintide Acetate?